Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0043—Nose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

• the present invention relates to methods of reducing airflow obstruction in the nasal passages, clearing a sinus infection, and reducing sinus pain in a patient. More specifically the present invention relates to methods of treating nasal rhinitis, sinusitis and nasal polyposis in patients and compositions useful for the same. Yet more specifically, the present invention relates to methods of treating the above using intranasally-administered recombinant human CC10 and compositions thereof useful for the same.
• Clara Cell “10 kDa” protein (CC10) or uteroglobin (UG) is a small, homodimeric secretory protein produced by several mucosal epithelia and other organs of epithelial origin (Mukherjee, 1999).
• CC10 consists of two identical subunits of 70 amino acid residues, each with the “four helical bundle” secondary structure motif, joined in antiparallel orientation by two disulfide bonds between Cys 3 and 69′, 3′ and 69 (Matthews, 1994; Morize, 1997). The homodimer containing two disulfide bonds appears to be its primary, extracellular active form.
• CC10 is an anti-inflammatory and immunomodulatory protein that has been characterized with respect to various interactions with other proteins, receptors and cell types (reviewed in Mukherjee, 2007, Mukherjee, 1999, and Pilon, 2000).
• CC10 protein or mRNA have been found in various tissue and fluid samples for a number of clinical conditions characterized by some degree of inflammation including asthma (Lensmar, 2000; Shijubo, 1999; Van Vyve, 1995), pneumonia (Nomori, 1995), bronchiolitis obliterans (Nord, 2002), sarcoidosis (Shijubo, 2000), and in patients suffering from chronic rhinitis with recurrent sinusitis and nasal polyposis (Liu, 2004). Pulmonary epithelial cells, the body's primary source for endogenous CC10, are often adversely affected in these conditions, depleted or even ablated (Shijubo, 1999).
• CC10 appears to be an autocrine and/or endocrine required for development of specific sets of non-ciliated respiratory epithelial cells and associated structures (Castro, 2000). Thus, it is still not known whether CC10 deficiency is a cause or an effect of the inflammation and/or the condition.
• Nasal rhinitis is an inflammation of the nasal passages and sinuses in the nasopharygeal cavity.
• rhinitis There are two types of rhinitis, allergic and non-allergic.
• Non-allergic rhinitis is due to viral, bacterial, or other infection, to exposure to inhaled chemicals or other irritants, or may be idiopathic, while allergic rhinitis is due to exposure to inhaled allergens.
• Allergic rhinitis may be seasonal, such as allergy to tree or grass pollen; or it may be perennial, such as allergy to dust mites and common molds. Rhinitis ranges in severity from mild seasonal discomfort due to itching, sneezing, and nasal discharge for a few hours, days or weeks, to painful and debilitating chronic sinus inflammation that is often associated with recurrent bacterial infection. Chronic sinus inflammation in the presence of bacterial infection is sometimes referred to as chronic rhinosinusitis (“CRS”). CRS, leads to irreversible remodeling and scarring of airway epithelia and sinus tissue.
• CRS chronic rhinosinusitis
• rhCC10 can alleviate inflammation, and at what dosage, in patients suffering from nasal rhinitis, especially chronic rhinitis and rhinosinusitis, with or without nasal polyposis and in patients suffering from chronic or recurrent bacterial sinus infection has remained elusive. In fact, as shown below, recent work indicates that at dosages known and commonly used, rhCC10 is ineffective:
• rhCC10 In a recent Phase II clinical study to evaluation the efficacy of intranasal rhCC10 to suppress nasal inflammation and rhinitis due to seasonal allergy, rhCC10 treatment resulted in a significant worsening of symptoms in one of six efficacy outcome measures compared to placebo (Widegren, et al., 2009). The remaining five efficacy outcome measures showed no difference between rhCC10 and placebo, although all trended in favor of placebo. RhCC10 was inferior to placebo in improving (increasing) peak nasal inspiratory flow and in mitigating rhinorrea caused by administration of aero-allergens. Table 1 shows comparative outcomes of patients while receiving rhCC10 versus outcomes in the same patients while receiving placebo, as measured during the last three days (days 5-7) of each treatment period.
• RhCC10 given once daily for seven days in this nasal allergen challenge model of seasonal allergic rhinitis.
• RhCC10 given 1.1 mg in 200 ⁇ L per day intranasally, did not favorably affect allergen-induced morning, post challenge or evening symptoms compared with placebo.
• a higher PNIF reflects greater airflow and a lower PNIF indicates restricted airflow.
• Morning as well as evening PNIF were unaffected by rhCC10, however, post challenge PNIF was modestly reduced by rhCC10 treatment compared to placebo, which did reach statistical significance.
• Symptom-scores and PNIF-levels reached in the placebo arm were very similar to those recorded historically in this model.
• markers of inflammation in nasal lavage fluids including levels of eosinophil cationic protein, myeloperoxidase, and alpha2-macroglobulin, and rhCC10 did not mediate any reduction in these markers compared to placebo.
• corticosteroids inhibit morning, post-challenge as well as evening symptoms and these markers of inflammation in nasal lavages (Ahlstrom-Emanuelsson et al., 2002 & 2007) whereas anti-histamines reduce post-challenge symptoms only (Korsgren et al. 2007). Therefore, using this dose, dosing regimen, volume and spray method of intranasal administration, rhCC10 did not demonstrate anti-allergy, anti-inflammatory effects in all six clinical outcome measures or in all three inflammatory markers in nasal lavages.
• nasal rhinitis and rhinosinusitis are treated with various over-the-counter and prescription medications such as anti-histamines, decongestants, non-steroidal anti-inflammatory agents (“NSAIDS”) and various non-pharmacologic nasal sprays and irrigation solutions.
• NSAIDS non-steroidal anti-inflammatory agents
• Chromium nasal solutions, oral anti-histamines and leukotriene receptor antagonists treat symptoms but provide only a few hours of relief.
• Nasal oxymetazoline solutions are very effective at opening nasal passages but overuse results in a “rebound effect” and rapid loss of efficacy with worsening of symptoms. Side effects for these types of drugs include sore throat, dehydration of nasal tissues, and constipation, among others.
• sinusitis is typically treated with oral antibiotics.
• Antibiotics range in side effects from mild to severe and can include constipation and other digestive problems, headache, dizziness, rashes, liver, kidney and bladder toxicity, muscle and joint pain, etc.
• Antibiotics can also cause hypersensitivity reactions, particularly in patients with recurrent sinusitis who have to take antibiotics repeatedly and eventually become allergic to them. Hypersensitivity reactions to antibiotics may occur without warning or previous signs of allergy and may be suddenly lethal.
• corticosteroids For severe and/or chronic rhinosinusitis disease, physicians currently prescribe nasal corticosteroids, which reduce inflammation but often lose efficacy after a few weeks or months of continuous therapy. Oral corticosteroids are also efficacious but have many undesirable side effects when used for long periods of time. For example, in adults, cardiovascular complications, including hypertension and stroke, are major side effects of corticosteroid use. In children, corticosteroids impair normal growth and development. In all patients, corticosteroids lower the patient's immune function and leave them susceptible to infection of all types (bacterial, viral, fungal, etc.).
• Particle sizes generated by the aforementioned devices are in the 5-10 micron range, which maximizes delivery and local deposition of the drug in the nasal mucosa lining the nasopharygeal cavity.
• the nasal mucosa is comprised of a normally thin layer of mucus that overlays the wet epithelium in the nasal passages and sinuses of the nasopharyngeal cavity. Most 5-10 micron particles sprayed into the nostril will impact the non-ciliated epithelium in the anterior portion of the nasopharyngeal cavity.
• drugs may distribute throughout the mucosa and be cleared at various rates through the action of cilia and ciliated epithelial cells located in the posterior two thirds of the nasopharyngeal cavity that push towards the pharynx where the drug and mucus are swallowed.
• the local action of drugs deposited in the nasal cavity depends upon the particle size delivered, the formulation, and the rate of clearance. These factors affect the efficiency of local delivery and the length of time that the nasopharyngeal mucosa and epithelia are exposed to the drug before it is cleared.
• intranasally administered drugs also depends upon the condition of the nasal mucosa and tissues at the time of delivery. For example, when the nasal passages are blocked by thick mucus, local delivery of drugs is very difficult, if not impossible.
• MDI metered dose inhaler
• MDI metered dose inhaler
• pharmaceutically-acceptable is intended to characterize a formulation or combination of excipients that cause no deleterious effects or cause deleterious effects that are known and are, or can be, accepted by regulatory authorities.
• rhCC10 in a dosage range given at appropriate intervals, or in one dose, to treat, cure or prevent nasal rhinitis, sinusitis, rhinosinusitis, and CRS, with or without nasal polyposis.
• rhCC10 offers an even greater benefit in treating, curing or prevention of chronic rhinitis when given in a dosage range at appropriate intervals, or in one dose.
• rhCC10 which was thought to be ineffective in curing, treating or preventing nasal inflammation, rhinitis, nasal rhinitis, chronic rhinitis, sinusitis and rhinosinusitis, is in fact effective when used in accordance with the invention herein.
• rhCC10 in a dosage range given at appropriate intervals or in one dose where a patient shows one or more of the following: sinus pain and pressure, inability to sleep due to sinus discomfort, chronic rhinitis, rhinosinusitis, and growth or regrowth of nasal polyps.
• rhCC10 such that it does not inhibit platelet aggregation, suppress the immune response, such as in common cold or flu, or increase the frequency or severity of any adverse event.
• rhCC10 is administered intranasally in a single dose divided about equally between each nostril in a range of 1.5 micrograms to 1.1 milligrams per day, or in multiple doses which taken together achieve this dosage range on a daily basis to treat, cure or prevent severe nasal rhinitis, nasal sinusitis, especially chronic rhinosinusitis, and/or nasal polyposis.
• an intranasal rhCC10 dose or doses divided about equally between each nostril in a range of 1.5 micrograms to 1.1 milligrams per day can be repeated at appropriate intervals to treat, cure or prevent severe nasal rhinitis, nasal sinusitis, chronic rhinitis with recurrent sinusitis, especially rhinosinusitis, and/or nasal polyposis.
• rhCC10 is administered intranasally on a daily basis consecutively for seven days, ten days, 14 days, or 21 days.
• rhCC10 is administered three times per day, at approximately eight hour intervals in intranasal doses divided about equally between each nostril in a range of 0.5 to 370 micrograms per day. In yet another aspect of the invention, rhCC10 is administered two times per day, at approximately twelve hour intervals in intranasal doses divided about equally between each nostril in a range of 0.75 to 650 micrograms per day.
• rhCC10 is administered in a tapered fashion, beginning with three times per day, at approximately eight hour intervals in intranasal doses divided about equally between each nostril in a range of 0.5 to 370 micrograms per day for three days, followed by two times per day, at approximately twelve hour intervals in intranasal doses divided about equally between each nostril in a range of 0.5 to 370 micrograms per day, followed by one time per day in intranasal doses divided about equally between each nostril in a range of 0.5 to 370 micrograms per day.
• rhCC10 is administered intranasally in accordance with the above aspects but in a dose or doses adding up to between about 15 nanograms and about 10 milligrams.
• rhCC10 can be given alone, in conjunction with, before or after other standard rhinitis and sinusitis treatments, including but not limited to intranasal or systemic corticosteroids, NSAIDs (including aspirin, COX-2 inhibitors), pain medications, antibiotics, antivirals, antifungals, decongestants, antihistamines, chromium solutions, nasal lavage, saline nasal lavage, and homeopathic remedies.
• NSAIDs including aspirin, COX-2 inhibitors
• rhCC10 can be used as an excipient and/or local anti-inflammatory, and/or local immunosuppressor, to facilitate the local nasal delivery or application for local delivery or systemic absorption of other drugs to the nasal tissues that may or may not irritate or otherwise elicit, or may elicit, an undesired local irritation at the site of application.
• rhCC10 may be used as an excipient for other drugs to alleviate or avoid discomfort associated with nasal delivery.
• rhCC10 can be used as an excipient or to alleviate the irritation caused by intranasal administration of other drugs for either local or systemic delivery.
• rhCC10 can be formulated as an aqueous solution, a suspension (containing a nasal surfactant excipient), or a gel (such as a hydrogel employing, for example, hydroxymethylcellulose), in order to achieve the proper viscosity for nasal application and local distribution profile in the nasopharyngeal cavity.
• rhCC10 can be formulated in combination with other active ingredients such as antibiotics or other antimicrobial agents, saline nasal lavages, decongestants, mucolytics, LTRA's, ⁇ -agonists, bronchodilators, etc.
• rhCC10 is formulated as an aqueous solution that is loaded into a nasal spray squeeze bottle, metered dose inhaler or spray pump device.
• rhCC10 is formulated as a suspension in a surfactant that is loaded into a nasal syringe-type application device, a metered dose inhaler, or other nasal application device.
• rhCC10 is formulated in a hydrogel, or other form of artificial mucus, and single doses are placed in a single use nasal swab device for intranasal application.
• the present invention relates to the critical dosages and timing of administration of rhCC10 to treat, cure or prevent nasal rhinitis and sinusitis, especially chronic nasal rhinitis with recurrent sinusitis, chronic rhinosinusitis, and nasal polyposis in humans.
• the rhCC10 is preferably obtained by the processes described in U.S. Patent Application Publication Nos. US 2003-0109429 and US 2003-0207795 attached hereto at Ex. A & B, respectively, both of which are incorporated by reference in their entirety, or via any other process which yields pharmaceutical grade (meeting FDA requirements) rhCC10.
• the rhCC10 of the embodiments of the present invention can be administered with, without, before or after other intranasal, pulmonary, or systemic therapy.
• rhCC10 is administered intranasally, to each nostril 1-3 times per day, for 7-14 days, and every other day thereafter for another 14 days, and thereafter as needed. More preferably, rhCC10 is administered as soon as the patient begins to experience sinus pain and pressure.
• a dose or multiple doses of rhCC10 equaling a dose ranging from about 1.5 micrograms to about 1.5 milligrams can be administered.
• rhCC10 can be administered in the dose range on a daily basis.
• rhCC10 can be administered in the dose range on a daily basis for at least seven days consecutively.
• rhCC10 can be administered in the dose range on a daily basis for at least 14 days consecutively.
• rhCC10 can be administered in the dose range every other day for 30 days consecutively.
• rhCC10 can be administered in tapered dosages daily for ten consecutive days, said tapered dosages comprising a high dose at each administration for the first three days, an intermediate dose at each administration for the second three days, and a low dose at each administration for the last four days.
• rhCC10 can be administered in the dose range or in tapered doses up to three times per day, approximately every eight hours.
• rhCC10 intranasally to the patient.
• the above doses of rhCC10 can be administered to the patient as an aerosol, by intranasal instillation, or by deposition of a gel or cream in nasal passages.
• rhCC10 in accordance with the methods described above, can be administered prior to, during or after an oral or intranasal decongestant, anti-histamine, corticosteroid, mucolytic, expectorant, mucus suppressor, surfactant, bronchodilator, vasoconstrictor, sinus pain analgesic, or other typical therapy.
• rhCC10 in accordance with the methods described above, can be administered to treat or prevent nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, or nasal polyposis in a patient.
• rhCC10 and application methods described above can be administered daily, more than once daily, three times daily, every other day or in a tapered fashion depending upon the severity of disease being treated, the patient's overall health, and whether an acute or chronic condition is being treated. For example, the more severe the disease condition, the higher the amount of rhCC10 would be required to effectively treat the disease.
• For maintenance therapy of chronic disease for example, to prevent an exacerbation of nasal rhinitis, nasal sinusitis, or nasal polyposis, lower doses would be used. It is understood that a physician would be able to monitor and adjust doses, formulations, and application methods as needed based on the patient's symptoms and responses to therapy and within the parameters and dose ranges described in the embodiments of the present invention.
• rhCC10 is maximally effective when applied directly to the local nasal epithelium, for example by use of a liquid formulation in a spray bottle, spray pump, or lavage. Therefore, it is sometimes necessary to use fast-acting local mucolytics, anti-histamines, and/or decongestants, as well as physical methods such as inhaling moist warm air, hot compresses applied to the face, and salt water nasal lavage to open up the nasal passages before rhCC10 can be applied effectively to the nasal epithelia.
• Intranasal instillation is another method for administering rhCC10 that can be accomplished using rhCC10 in either a liquid or gel formulation.
• the gel dosage formulation provides the advantage of better local dosing over a longer period of time by retaining the dose of rhCC10 in the local nasal area in which it was swabbed longer, whilst liquid dosages may be partially swallowed following instillation due to normal nasal drainage resulting in much shorter local exposures and smaller local doses.
• intranasal instillation of a liquid dosage form by nasal lavage using a “neti pot” type of device, confers the advantage that the dose is more immediately distributed over a larger surface area in the nasal tissues and sinuses, than a local application gel formulation.
• rhCC10 can be formulated with several nasal excipients for intranasal delivery. These include excipients to adjust the pH of the drug, to buffer the drug to maintain solubility, to act as preservatives or enhance preservatives for prevention of microbial growth and/or transfer, to adjust the tonicity, solubility, or viscosity of the drug, to enhance penetration or permeation of the drug (systemic delivery), to modify the local bioavailability and half-life of the drug (increase viscosity), to reduce toxicity, to suspend insoluble drugs, and to alter the taste of the formulation.
• Table 2 contains a non-exclusive list of exemplary excipients and their functions in intranasal formulations of rhCC10. Any single excipient or combination of excipients can be used to formulate rhCC10 for intranasal administration.
• rhCC10 can also be formulated in combination with other drugs, artificial mucus, or other active ingredient for intranasal administration.
• Drugs with which rhCC10 can be formulated for intranasal administration include, but are not limited to, local or systemic antimicrobial agents (antivirals, antibacterials, antifungals), decongestants, anti-histamines, mucolytics, expectorants, leukotriene receptor antagonists, bronchodilators, beta 2 -adrenergic receptor agonists, local-acting vasoconstrictors (such as oxymetazoline), anti-inflammatory agents, and analgesic agents.
• Still other drugs with which rhCC10 can be formulated for intranasal administration for local or systemic effects include anti-inflammatory agents, beta 2 -adrenergic receptor agonists, anti-cancer agents, anti-angiogenic agents, anti-fibrotic agents, immunomodulatory agents, vaccines, metabolic agents, analgesics, neuroleptic agents, anesthetics, agents for depression and other psychiatric disease (mental health), anti-addiction agents, homeopathic remedies, herbal preparations, vitamins and minerals and the like.
• rhCC10 is compatible with most non-reactive chemicals and drugs, including hydrophilic and hydrophobic chemicals, nucleic acids and nucleic acid analogs, proteins and peptides, carbohydrates, lipids and phospholipids, etc.
• hydrophilic and hydrophobic chemicals including hydrophilic and hydrophobic chemicals, nucleic acids and nucleic acid analogs, proteins and peptides, carbohydrates, lipids and phospholipids, etc.
• rhCC10 is ideally suited to enhance the delivery of other drugs via the nasal passages.
• rhCC10 can also act as a local anti-inflammatory agent that can be used as an excipient to suppress painful local nasal responses at the site of administration of other drugs, such as, for example, chemotherapeutic agents and drugs that produce a “burning sensation” upon administration.
• a key parameter relevant to drug efficacy associated with intranasally administered rhCC10 is the concentration of the rhCC10 itself.
• Formulations in which the rhCC10 concentration is too high (i.e. above 2 mg/ml) have demonstrated null or even detrimental effects, as evidenced by the clinical outcomes described in the Background.
• the rhCC10 formulation was 5.6 mg/ml and was applied directly to the patient's nostrils (Widegren, et al. 2009).
• the rhCC10 concentration was 250-262 micrograms/ml, a clinical benefit was conferred.
• the phenomenon may be related to the very high sphere of hydration for rhCC10, that is, the number of water molecules coordinated by CC10 is higher than the average protein.
• Administration of high concentrations of CC10 to mucosal and other bodily fluids may result in the “subtraction” or loss of water from the local fluids, thereby causing a local dehydration and detrimental disruption in the equilibria between substances in the local biological milieu.
• an acute local over-abundance of CC10 may also result in desensitization of cells and tissues to the presence of CC10, effectively reducing the potency of the drug rather than increasing the pharmacologic effect.
• rhCC10 feedback inhibition of a pathway or set of pathways involving a particular metabolite or mediator may actually result in the opposite effect (activation versus suppression and vice versa) than may be observed at lower doses of the metabolite or mediator.
• a cutoff for rhCC10 formulations intended to be administered to nasal and other mucosal surfaces by intranasal, intratracheal or other local/topical administration is 2 mg/ml, above which rhCC10 is not efficacious and can even be detrimental.
• RhCC10 was produced in E. coli bacteria and purified by a process (Claragen, Inc., College Park, Md.), described in U.S. Application Publication Nos. US 2003-0109429 and US 2003-0207795, both of which are incorporated by reference in their entirety.
• the protein for the study was provided as a >98% pure solution of recombinant human CC10 homodimer.
• the biological activity of each batch was compared using a proprietary secretory PLA 2 inhibition assay, described in U.S. Application Publication Nos. US 2002-0169108 which is incorporated herein by reference.
• Patient responses to nasal allergen challenges in the absence of rhCC10 were first measured and baseline data recorded. A total of 39 patients were screened for inclusion in the study. All patients were male subjects, aged 18-50 years, with Body Mass Index between 18 and 28 kg/m 2 , and a history of birch and/or timothy pollen-induced seasonal allergic rhinitis for at least the previous 2 years and otherwise healthy. Each patient had elevated specific IgE or at least one positive skin prick test (SPT) to at least one aero allergen (eg. timothy or birch pollen) and each patient exhibited symptoms provoked by the allergen with a corresponding elevated specific IgE or positive SPT. Subjects were excluded from the study if they had perennial allergy (e.g.
• Rhinorrea is defined as a discharge from the nasal mucus membranes and is typically watery. All allergen administrations were performed in the clinic by hospital staff.
• Analgesics including aspirin but not ibuprofen
• Clarityn® Clarityn® 10 mg
• test agents placebo and rhCC10
• 10 ml glass vials labeled numerically so that doctors and patients in the clinic would not be able to distinguish between them.
• a key was maintained in the hospital pharmacy and doctors were to be informed of the identity of each vial only in the event of an adverse event in which the doctor would need the information to treat the patient.
• a disposable medical nasal spray device manufactured by Valois Pharm (France), was connected to the 10 mL vials at the clinical site just before administration. This device consisted of a pump (VP7/100S 18PH), an actuator (PR147) and a cap (B25/A). Placebo consisted of sterile, unbuffered 0.9% sodium chloride.
• the rhCC10 was in sterile unbuffered 0.9% sodium chloride at a concentration of 5.6 mg/ml. Both placebo and rhCC10 appeared as clear, colorless, odorless liquids that could not be readily distinguished.
• a total of 100 microliters of placebo or rhCC10 was administered to each nostril of each patient on each day of treatment for a total of seven consecutive days of treatment in each treatment period. All allergen and test agent administrations were performed in the clinic by hospital staff.
• the total daily dose of rhCC10 was 1.1 milligrams per day, administered in a single dose as an aerosol sprayed in a 100 microliter volume to each nostril, or 0.56 milligrams per nostril.
• the rhCC10 was administered 15′-30′ prior to administration of allergen.
• TNSS Total Nasal Symptom Score
• Nasal symptoms including nasal congestion, rhinorrea and snez/itchy nose were scored by the patients and recorded in the patient diary prior to administration of study medication in the morning (rating symptoms during the preceding 12 h, but disregarding possible symptoms the first 15 minutes post study medication).
• TNSS was recorded 15 minutes after each allergen challenge.
• the scores were added to constitute a total score, per time point, which ranged from 0 to 9.
• Mean nasal symptom scores, for morning recordings, for recordings 10 minutes after allergen challenge, and for evening recordings, respectively, of the last three days of each allergen challenge period was used in the statistical analysis.
• Peak Nasal Inspiratory Flow PNIF
• PNIF was measured by the patients before the intake of the drug in the morning, 10 minutes after the allergen challenge, and in the evening. The measurements were carried out using a PIF-meter (Clements-Clarke, Harlow, U. K.) equipped with a facial mask. Patients stood up during the procedure, placed the mask snugly over the face with both hands, closed the mouth and inhaled through the nose. They recorded the value and returned the device to a reading of 30, then repeat the procedure 2 more times. The highest value of the three measurements was recorded in the diary. Similar to the nasal symptom score, PNIF recordings, per time point, of the last three days of each allergen challenge period were used in the statistical analysis.
• Loratadin is a non-sedating antihistamine, paracetamol, is an analgesic and antipyretic, flutikason (fluticasone) is a corticosteroid anti-inflammatory agent, oxymetazoline is a selective alpha-1 agonist and partial alpha-2 agonist topical decongestant, and ebastin is a non-sedating H 1 antihistamine.
• flutikason fluticasone
• oxymetazoline is a selective alpha-1 agonist and partial alpha-2 agonist topical decongestant
• ebastin is a non-sedating H 1 antihistamine.
• AEs adverse events
• SAEs serious adverse events
• An AE is any untoward medical occurrence in a subject or a clinical investigation temporally associated with the use of the investigational drug whether or not the event is considered to have a causal relationship with the drug.
• a pre-existing condition i.e., a disorder present before the AE reporting period started and noted on the pre-treatment medical history/physical examination form
• Serious adverse events were defined as any untoward medical occurrence that, at any dose; 1) results in death, 2) is life-threatening, 3) requires hospitalization or prolongation of an existing hospitalization, 4) results in disability/incapacity, 5) is a congenital anomaly/birth defect, 6) is an important Other Medical Event (OME), and 7) all grade 4 laboratory abnormalities.
• the AE reporting period for began upon receiving the first dose of investigational medication and ended at the 2-week post discontinuation of investigational medication visit (follow-up visit).
• intranasal rhCC10 administration was found to be safe and well-tolerated in humans when given once daily as an aerosol in a divided dose of 1.1 milligrams, 0.56 milligrams per nostril, for seven consecutive days.
• rhCC10 An 11 mg (2 mls) aliquot of rhCC10 was added to a soft plastic squirt bottle containing 42 mls of sterile 0.65% saline containing disodium and monosodium phosphate, and phenylcarbinol (preservative) plus benzylkonium chloride (preservative), or 0.1% thimerosol (also a preservative), creating a 250 microgram/ml solution of rhCC10.
• the patient self-administered the rhCC10 by inserting the applicator end of the bottle to the nose, such that the aperture that dispenses the drug is held inside the nostril, and simultaneously squeezing and inhaling.
• a simple aerosol is created when the bottle is rapidly squeezed, forcing liquid through a small pinhole at the top of the nasal applicator end.
• the volume and dose delivered depends upon the rapidity of the squeeze and force exerted. Volumes ranging from 25-500 microliters, corresponding to 6.6-131 micrograms of rhCC10, are typically dispensed. When the squeeze is harder and larger volumes are delivered, the nasal passages are lavaged and part of the dose may be swallowed or flow into the trachea over a period of several minutes.
• rhCC10 was administered to a patient suffering from episodic and/or chronic sinus pain due to chronic rhinosinusitis, stemming from perennial allergies, with recurrent bacterial sinus infections.
• the patient's history includes; 1) antibiotics prescribed from two to twelve times per year for sinus infection in the past six years, 2) intranasal corticosteroids prescribed and taken as needed for the past six years, and 3) non-prescription analgesics, decongestants and anti-histamines taken daily to relieve sinus pain, nasal and chest congestion, and enable the patient to sleep through the night.
• RhCC10 was a useful substitute and adjunctive therapy for the patient in the following doses, dosing regimen, formulations, and drug-device combinations.
• the total daily dose intake using this method ranged from 78.6-1,572 micrograms total (39.3-786 micrograms per nostril), corresponding to 1.1 micrograms/kg-22.5 micrograms/kg of body weight per day in the average 70 kg patient.
• the patient discontinued use.
• the patient received rhCC10 in the formulation and spray bottle of Example 4, twice per day, in the morning and evening, starting within 12 hours of sensing the first sinus pain.
• the sinus pain was associated with the recurrence of a bacterial sinus infection that had been treated for 14 days with a powerful broad-spectrum antibiotic (eg. Levaquin), during which time the pain abated, but returned within four days of ending the antibiotic.
• a powerful broad-spectrum antibiotic eg. Levaquin
• Known side effects associated with the antibiotic occurred in the patient, including constipation and irritable bowels, chest pain, dizziness, transient numbness and tingling in the extremities, extreme sunburn, and increased susceptibility to bruising.
• the doctor advised the patient to avoid further use of the antibiotic.
• rhCC10 Maintenance therapy with rhCC10 to prevent sinus pain and infection, often arising from seasonal or perennial allergy and exposure to airborne allergens, is also possible.
• Daily intranasal administration of rhCC10, at a formulation concentration not to exceed 500 micrograms/ml (preferably not to exceed 250 micrograms/ml), in doses of 26.2-524 micrograms total, given in single or multiple actuations per nostril, corresponding to 374 nanograms/kg-7.5 micrograms/kg of body weight) for up to two and one half months would safely control chronic rhinitis symptoms, rhinosinusitis, nasal and chest congestion, sinus infection and pain, and sleeplessness, and prevent the need for antibiotics, analgesics (NSAIDS such as aspirin, ibuprofen), decongestants, anti-histamines, and sleep-inducing drugs.
• NAIDS analgesics
• rhCC10 was efficacious in the alleviation of symptoms associated with chronic rhinitis and bacterial sinus infection (aka chronic rhinosinusitis).
• chronic rhinitis and bacterial sinus infection aka chronic rhinosinusitis.
• several other antibiotics Amoxicillin, Zithromax, Biaxin, etc.
• rhCC10 was used without an antibiotic, thus, sparing the patient the negative side effects associated with the antibiotic. No adverse events were associated with potential interactions between rhCC10, decongestants, antihistamines, and antibiotics.
• decongestants and antihistamines and antibiotics commonly prescribed for nasal sinusitis were either avoided entirely or used safely in conjunction with rhCC10 to alleviate moderate to severe nasal symptoms.
• antibiotics Prior to receiving rhCC10, the patient had been on antibiotics for 5 weeks (amoxicillin; 500 mg/day; 10 days; then augmentin, 4 grams/day for 3 weeks) and on intranasal corticosteroid treatment for 10 days (fluticasone propionate).
• rhCC10 Immediately prior to receiving rhCC10, both sides of his nasal septum were blood red and contained readily visible dilated capillaries, indicating the presence of severe local inflammation.
• a 250 microgram/ml solution of rhCC10 in 0.65% saline containing disodium and monosodium phosphate, phenylcarbinol (preservative) and benzylkonium chloride (preservative) was then administered in a single intranasal dose as a spray into each nostril at a dose of approximately 20-50 micrograms per nostril.
• rhCC10 Approximately 12 hours after receiving the single intranasal dose of rhCC10, his nasal septum was a normal dusky purple with no dilated capillaries visible, indicating a profound local anti-inflammatory effect. The patient continued on rhCC10, twice daily, for 7 days, noting decreased sinus pain and pressure symptoms.
• the dosing regimen of rhCC10 was to be tapered from two squirts per nostril, twice per day for 3 days, to one squirt per nostril twice per day for 3 days, to one squirt per nostril once per day for 3 days. The patient continued with this regimen for 4 days.
• the rhCC10 was administered on the same schedule by a lavage technique to increase access of rhCC10 to the surfaces of the ethmoid sinus region.
• a lavage method a total dose of 250 micrograms of rhCC10 (i.e. 1 ml of the 250 microgram/ml solution) was added to 118 mls (1 ⁇ 2 cup; 4 fluid ounces) of a standard commercially available nasal lavage solution.
• the patient received the lavage in the supine position with head tilted back, allowing the rhCC10 formulation to settle in the sinuses for 3-5 minutes.
• rhCC10 mediated a potent anti-inflammatory response, which was caused by a bacterial infection and not allergy.
• rhCC10 further mediated an anti-inflammatory response when standard anti-inflammatory therapy in the form of intranasal corticosteroids failed.
• rhCC10 also facilitated clearance of the bacterial infection, which resolved without the use of additional antibiotics.
• rhCC10 mediated a complete recovery of the nasal epithelia, avoiding the scarring, fibrosis, and epithelial thickening that typically accompanies such severe infections.
• rhCC10 Intranasal delivery of rhCC10 is useful for example, when treating upper respiratory (nasal and sinus and upper airway) inflammation and fibrosis, due to perennial allergy, infection, or some other form of acute or chronic upper respiratory irritation.
• rhCC10 is soluble in a wide range of aqueous solutions, over a wide range of pH values, for example 3.9-8.5, and in a wide range of salt concentrations (for example 0.1%-4%), as well as a variety of alcohol/water mixtures (for example 0.1%-90% ethanol).
• rhCC10 has the solubility and stability characteristics, to be used with a wide range of intranasal dispensing devices, including, but not limited to, for example, simple squirt bottles with uncontrolled volumetric doses for self-administration of liquid aerosols, pump-action or pressurized canister metered dose devices for self-administration of liquid aerosols, propellant-driven dry powder or liquid aerosol metered dose devices for self-administration, gel-laden nasal swabs for topical delivery to the nasal passages, and drug-loaded syringes for deeper topical administration and sinus lavage, for voluntary or involuntary administration to the conscious or unconscious patient.
• simple squirt bottles with uncontrolled volumetric doses for self-administration of liquid aerosols pump-action or pressurized canister metered dose devices for self-administration of liquid aerosols, propellant-driven dry powder or liquid aerosol metered dose devices for self-administration, gel-laden nasal swabs for topical delivery to the nasal passages, and drug-loaded sy
• the critical ranges for rhCC10 dosages effective to safely treat, cure and prevent nasal rhinitis, especially non-allergic rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis have been found. Accordingly, the present invention provides a safe and well-tolerated intranasal rhCC10 based therapy effective at treating the symptoms of nasal rhinitis, especially non-allergic rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis thus reducing the significant morbidities in child and adult patients suffering from these conditions, while not causing any dangerous side effects.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Zoology (AREA)
• Otolaryngology (AREA)
• Marine Sciences & Fisheries (AREA)
• Oncology (AREA)
• Pulmonology (AREA)
• Communicable Diseases (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Inorganic Chemistry (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (3)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=41319290

Family Applications (3)

Family Applications After (2)

Country Status (12)

Cited By (10)

Families Citing this family (2)

Citations (2)

Family Cites Families (37)

• 2009
  • 2009-05-12 CN CN2009801169194A patent/CN102292099A/zh active Pending
  • 2009-05-12 EP EP16164414.1A patent/EP3085382A1/fr not_active Withdrawn
  • 2009-05-12 WO PCT/US2009/043613 patent/WO2009140269A2/fr not_active Ceased
  • 2009-05-12 KR KR1020107028003A patent/KR20110014199A/ko not_active Ceased
  • 2009-05-12 NZ NZ600803A patent/NZ600803A/en not_active IP Right Cessation
  • 2009-05-12 AU AU2009246543A patent/AU2009246543B2/en not_active Ceased
  • 2009-05-12 EP EP09747353A patent/EP2303308A4/fr not_active Ceased
  • 2009-05-12 CA CA2724277A patent/CA2724277A1/fr not_active Abandoned
  • 2009-05-12 NZ NZ588895A patent/NZ588895A/en not_active IP Right Cessation
  • 2009-05-12 MX MX2010012234A patent/MX2010012234A/es active IP Right Grant
  • 2009-05-12 JP JP2011509615A patent/JP5773437B2/ja active Active
  • 2009-05-12 BR BRPI0911945A patent/BRPI0911945A2/pt not_active IP Right Cessation
• 2010
  • 2010-10-26 IL IL208940A patent/IL208940A0/en unknown
  • 2010-11-12 US US12/945,622 patent/US20110240012A1/en not_active Abandoned
• 2016
  • 2016-02-12 US US15/042,790 patent/US9844580B2/en active Active
• 2017
  • 2017-11-10 US US15/809,357 patent/US20180125931A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events